Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2018 ASCO Annual Meeting!


Session: Head and Neck Cancer

Type: Poster Session

Time: Saturday June 2, 1:15 PM to 4:45 PM

Location: Hall A


Session: Head and Neck Cancer

Type: Poster Discussion Session

Time: Saturday June 2, 4:45 PM to 6:00 PM

Location: S100a

Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).

Sub-category:
Biomarkers/Epidemiology/Outcomes

Category:
Head and Neck Cancer

Meeting:
2018 ASCO Annual Meeting

Abstract No:
6019

Poster Board Number:
Poster Discussion Session (Board #7)

Citation:
J Clin Oncol 36, 2018 (suppl; abstr 6019)

Author(s): Bouchra Tawk, Juergen Debus, Christian Schwager, Annett Linge, Ute Ganswindt, Inge Tinhofer, Volker Budach, Martin Stuschke, Panagiotis Balermpas, Franz Rödel, Anca Grosu, Daniel Zips, Stephanie E. Combs, Mechthild Krause, Wilko Weichert, Michael Baumann, Claus Belka, Gerhard Dyckhoff, Christel Herold-Mende, Amir Abdollahi; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), core center Heidelberg, Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), partner site Dresden, Dresden, Germany; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), partner site Munich, Munich, Germany; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), partner site Berlin, Berlin, Germany; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), partner site Essen, Essen, Germany; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), partner site Frankfurt, Frankfurt, Germany; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, Germany; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), partner site Tübingen, Tübingen, Germany; German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), core center Heidelberg and partner site Dresden, Heidelberg, Germany

Abstract Disclosures

Abstract:

Background: Human Papilloma Virus (HPV)-driven head and neck cancer (HNSCC) is associated with good prognosis. The prognostic value of HPV-DNA and p16 IHC was recently reported by this consortium. Discordance between HPV and p16 status is consistently observed impacting patient stratification and treatment outcome. We sought to overcome this limitation by developing a next-generation methylome-based classifier of HPV-driven HNSCC. Methods: HPV-DNA and p16 status of a DKTK-ROG multicenter retrospective cohort of patients (n = 194) with oropharynx cancer (OPC), oral cavity- and hypopharynx cancer (non-OPC), homogenously treated with surgery and adjuvant cisplatin-based radiochemotherapy (RCHT), was employed as a training set. Five validation cohorts were utilized including DKTK-ROG patients with definitive RCHT (n = 110), three additional RCHT cohorts from Heidelberg, Dresden, Munich (n = 222) and The Cancer Genome Atlas – HNSCC cohort (TCGA, n = 206). Overall methylome data from 732 samples including two different sources (FFPE/FrFr) and platforms (Illumina 450K and EPIC 850K) were studied. Results: A 24-probe set methylome-based classifier of HPV-driven HNSCC was discovered (HPV-M) to significantly correlate with improved clinical outcomes: HR for local recurrence (range 0.11-0.19), disease progression (range 0.16-0.29) and overall survival (OS, range 0.19-0.42) were significant in all cohorts (p < 0.05). Notably, HPV-M+ classification was superior to HPV-DNA+ status or p16+ IHC in predicting OS in all cohorts independent of tumor localization (OPC/non-OPC). Likewise, HPV-M showed a strong correlation with HPV-DNA and p16 status (p < 0.0001). Across cohorts ~ 10% discordance between HPV-M and HPV-DNA or p16 status was found, respectively. Among these patients (n = 71), OS was significantly reduced in patients with HPV-M negative vs. positive tumors (p < 0.009). Conclusions: We present a novel robust and independent methylome-based classifier of HPV-driven HNSCC that could be instrumental for accurate patient stratification in the era of de-escalation trials.

 
Other Abstracts in this Sub-Category:

 

1. Survival outcomes by HPV status in non-oropharyngeal head and neck cancers: A propensity score matched analysis of population level data.

Meeting: 2018 ASCO Annual Meeting Abstract No: 6005 First Author: Sibo Tian
Category: Head and Neck Cancer - Biomarkers/Epidemiology/Outcomes

 

2. High-accuracy HPV testing versus p16 IHC using multiple clinically relevant outcomes: The University of Chicago Experience.

Meeting: 2018 ASCO Annual Meeting Abstract No: 6020 First Author: Sara Kochanny
Category: Head and Neck Cancer - Biomarkers/Epidemiology/Outcomes

 

3. Absolute lymphocyte count (ALC) during and after chemoradiation (CRT) for squamous cell carcinoma of the head and neck (SCCHN): Effect of the regimen and potential therapeutic implications.

Meeting: 2018 ASCO Annual Meeting Abstract No: 6042 First Author: Marit Uglane
Category: Head and Neck Cancer - Biomarkers/Epidemiology/Outcomes

 

More...